Presentation Information
[27P-pm230]Evaluation of the activity and utility of Resmetirom using a mutant of the thyroid hormone receptor β1.
○Mana Mitsutani1, Hiromi Hano1, Mei Yokoyama1, Aoi Morita1, Midori Matsushita1, Tetsuya Tagami2, Kenji Moriyama1,2 (1. Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 2. Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center)